SCHEMBL6744822

SCHEMBL6744822

COc1ccc(CS(=O)(=O)C(CNC(=O)c2ccccc2)C(=O)NCC#N)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 7/20 0.52
OPRK1 P41145 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CXCR3 P49682 2/20 0.47
CTSS P25774 5/20 0.46
CTSK P43235 3/20 0.46
CTSB P07858 3/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
OPRM1 P35372 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6061910 0.90 CTSL (0.56) CTSLCTSSCTSKCTSB
SCHEMBL6737611 0.89 CTSL (0.53) CTSLNPC1RAB9AMEN1KMT2A
SCHEMBL6737517 0.88 CTSL (0.49) CTSLALDH1A1NPC1RAB9ACTSS
SCHEMBL6740960 0.88 CTSL (0.51) CTSLCXCR3CTSSCTSKCTSB
SCHEMBL6737869 0.87 CTSL (0.48) CTSLCTSSCTSKCTSB
SCHEMBL7664695 0.87 ESRRG (0.52) CTSLNPC1RAB9ACTSSCTSK
SCHEMBL7655925 0.87 CTSL (0.49) CTSLCTSSCTSKCTSB
SCHEMBL7666762 0.87 CTSL (0.48) CTSLOPRK1CTSSCTSKCTSB
SCHEMBL7667375 0.87 CTSL (0.49) CTSLCTSSCTSKCTSB
SCHEMBL7654250 0.85 CTSL (0.52) CTSLCTSSCTSKCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSL 10/4885OPRK1 1780/4885ALDH1A1 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.